LEX
Resources
Lex by email
Sign up
FT.com subscribers can now receive three email packages: Lex live, Lex alerts and Best of Lex
Principal content
Takeda / Amylin
A commitment to spend hundreds of millions of dollars on developing obesity drugs is the latest move by a Japanese drugmaker to shore up growth by expanding abroad
US health insurers
For the managed care companies at the centre of America’s health system, the political horse-trading has sent their shares gyrating
Novo Nordisk
Bosses of most drug companies must wish they had the Danish drugmaker‘s problems. What is the secret of its success?
Obamacare
Now that one version of the healthcare reform has passed a key Senate committee, supporters face a determined new opponent – one another.
Long-term care insurers
In the US, decay is often more ruinous than death and some insurers are more ill than their customers
PPR spin-offs
The French conglomerate’s decision to spin off a majority stake in CFAO, its African car and drugs distribution arm, is welcome
Abbott Laboratories / Solvay
The US pharma group‘s acquisition of the Belgian drugs company is about earnings and better access to overseas markets
Sinochem / Nufarm
The latest deal by China’s largest chemicals trader illustrates the growing verve of outbound M&A efforts by China’s state-owned enterprises
HIV vaccine
The experimental vaccine that appears to reduce the rate of infection is a promising first jab in a big fight
Dainippon Sumitomo / Sepracor
Long content to slug it out in their fragmented, $70bn-a-year domestic market, Japanese drugmakers have had something of a coming-out party
